Transdermal selegiline for the treatment of major depressive disorder

References

• Clinical Trials. gov2007 [online]National Library of MedicineAccessed June 26, 2007 URL: www.clinicaltrials.gov
   Google Scholar
• AmsterdamJD2003A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorderJ Clin Psychiatry642081412633131
   PubMed Web of Science ®Google Scholar
• AmsterdamJDBodkinJA2006Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trialJ Clin Psychopharmacol265798617110814
   PubMed Web of Science ®Google Scholar
• [APA] American Psychiatric Association2000Practice guideline for the treatment of patients with major depressive disorder (revision). APAAm J Psychiatry157Suppl145
   Google Scholar
• AzzaroAJVandenbergCMBlobLF2006Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjectsJ Clin Pharmacol469334416855078
   PubMed Web of Science ®Google Scholar
• AzzaroAJVandenbergCMZiemniakJ2007aEvaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteersJ Clin Pharmacol479789017554106
   PubMed Web of Science ®Google Scholar
• AzzaroAJZiemniakJKemperE2007bSelegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medicationsJ Clin Pharmacol471465817244765
   PubMed Web of Science ®Google Scholar
• BarrettJSHochadelTJMoralesRJ1996Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderlyAm J Ther36889811862224
   PubMedGoogle Scholar
• BieckPRAntoninKH1988Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjectsJ Clin Psychopharmacol8237453209716
   PubMed Web of Science ®Google Scholar
• BlackwellB1963Hypertensive crisis due to monoamine-oxidase inhibitorsLancet388495014056007
   PubMed Web of Science ®Google Scholar
• BlackwellBMabbittLA1965Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibitionLancet629384014275713
   PubMed Web of Science ®Google Scholar
• BlackwellBMarleyEPriceJ1967Hypertensive interactions between monoamine oxidase inhibitors and foodstuffsBr J Psychiatry113349656034391
   PubMed Web of Science ®Google Scholar
• BlobLFSharoskyMCampbellBJ2007Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hourCNS Spectr12253417192761
   PubMed Web of Science ®Google Scholar
• BodkinJAAmsterdamJD2002Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in out-patientsAm J Psychiatry15918697512411221
   PubMed Web of Science ®Google Scholar
• BridgeJAIyengarSSalaryCB2007Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trialsJAMA29716839617440145
   PubMed Web of Science ®Google Scholar
• ClaryCMandosLASchweizerE1990Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressantsJ Clin Psychiatry51226312347859
   PubMed Web of Science ®Google Scholar
• CooperAJ1989Tyramine and irreversible monoamine oxidase inhibitors in clinical practiceBr J PsychiatrySuppl 63845
   Google Scholar
• Da PradaMZurcherGWuthrichI1988On tyramine, food, beverages and the reversible MAO inhibitor moclobemideJ Neural Transm, Suppl2631563283290
   PubMedGoogle Scholar
• EvansRWBigalMEGrosbergB2006Target doses and titration schedules for migraine preventive medicationsHeadache46160416412164
   PubMed Web of Science ®Google Scholar
• FeigerADRickelsKRynnMA2006Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trialJ Clin Psychiatry6713546117017821
   PubMed Web of Science ®Google Scholar
• FeinbergSS2004Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indicationJ Clin Psychiatry651520415554766
   PubMed Web of Science ®Google Scholar
• GeorgotasAMcCueREHapworthW1986Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderlyBiol Psychiatry211155663756264
   PubMed Web of Science ®Google Scholar
• GoldbergLI1964Monoamine oxidase inhibitors. adverse reactions and possible mechanismsJAMA1904566214197995
   PubMed Web of Science ®Google Scholar
• GordonMNMullerCOShermanKA1999Oral versus transdermal selegiline: antidepressant-like activity in ratsPharmacol Biochem Behav63501610418793
   PubMed Web of Science ®Google Scholar
• HidestrandMOscarsonMSalonenJS2001CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson’s disease, as revealed from experiments with recombinant enzymesDrug Metab Dispos291480411602525
   PubMed Web of Science ®Google Scholar
• HoffmanBBLefkowitzRJHardmanJGLimbirdLEMolinoffPB1996Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonistsGoodman and Gilman’s The Pharmacological basis of therapeuticsNew YorkMcGraw-Hill199248
   Google Scholar
• HoutsmullerEJNotesLDNewtonT2004Transdermal selegiline and intravenous cocaine: safety and interactionsPsychopharmacology (Berl)172314014605792
   PubMed Web of Science ®Google Scholar
• KamadaTChowTHiroiT2002Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomesDrug Metab Pharmacokinet1719920615618670
   PubMedGoogle Scholar
• KesslerRCBerglundPDemlerO2003The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA289309510512813115
   PubMed Web of Science ®Google Scholar
• LiebowitzMRHollanderESchneierF1990Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disordersActa Psychiatr ScandSuppl3602934
   Google Scholar
• LiebowitzMRSchneierFCampeasR1992Phenelzine vs atenolol in social phobia. A placebo-controlled comparisonArch Gen Psychiatry492903001558463
   PubMed Web of Science ®Google Scholar
• LinEHVon KorffMLudmanEJ2003Enhancing adherence to prevent depression relapse in primary careGen Hosp Psychiatry253031012972220
   PubMed Web of Science ®Google Scholar
• MahmoodI1997Clinical pharmacokinetics and pharmacodynamics of selegiline. An updateClin Pharmacokinet33911029260033
   PubMed Web of Science ®Google Scholar
• MannJJAaronsSFWilnerPJ1989A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl. A selective monoamine oxidase inhibitorArch Gen Psychiatry4645502491941
   PubMed Web of Science ®Google Scholar
• MawhinneyMColeDAzzaroAJ2003Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissuesJ Pharm Pharmacol55273412625864
   PubMed Web of Science ®Google Scholar
• McDanielKD1986Clinical pharmacology of monoamine oxidase inhibitorsClin Neuropharmacol9207343521845
   PubMed Web of Science ®Google Scholar
• McGrathPJStewartJWFavaM2006Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D reportAm J Psychiatry163153141 quiz 166616946177
   PubMed Web of Science ®Google Scholar
• McGrathPJStewartJWHarrisonW1987Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressantPsychopharmacol Bull23169723602314
   PubMedGoogle Scholar
• OlfsonMMarcusSCTedeschiM2006Continuity of antidepressant treatment for adults with depression in the United StatesAm J Psychiatry163101816390896
   PubMed Web of Science ®Google Scholar
• QuitkinFMStewartJWMcGrathPJ1988Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI respondersAm J Psychiatry145306113278631
   PubMed Web of Science ®Google Scholar
• RabkinJQuitkinFHarrisonW1984Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative studyJ Clin Psychopharmacol427086386898
   PubMed Web of Science ®Google Scholar
• ReimannIWFirkusnyLAntoninKH1992Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differencesEur J Clin Pharmacol42137411618243
   PubMed Web of Science ®Google Scholar
• RooseSPGlassmanAHWalshBT1986Tricyclic nonresponders: phenomenology and treatmentAm J Psychiatry14334583953869
   PubMed Web of Science ®Google Scholar
• SacktorNSchifittoGMcDermottMP2000Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled studyNeurology54233510636157
   PubMed Web of Science ®Google Scholar
• SalonenJSNymanLBoobisAR2003Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systemsDrug Metab Dispos31109310212920164
   PubMed Web of Science ®Google Scholar
• Saura MartiJKettlerRDa PradaM1990Molecular neuroanatomy of MAO-A and MAO-BJ Neural TransmSuppl324953
   Google Scholar
• SchulzRAntoninKHHoffmannE1989Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegilineClin Pharmacol Ther46528362510962
   PubMed Web of Science ®Google Scholar
• ShinHS1997Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolitesDrug Metab Dispos25657629193866
   PubMed Web of Science ®Google Scholar
• ShulmanKIWalkerSE1999Refining the MAOI diet: tyramine content of pizzas and soy productsJ Clin Psychiatry60191310192596
   PubMed Web of Science ®Google Scholar
• ShulmanKIWalkerSEMacKenzieS1989Dietary restriction, tyramine, and the use of monoamine oxidase inhibitorsJ Clin Psychopharmacol93974022592589
   PubMed Web of Science ®Google Scholar
• SimonGE2006The antidepressant quandary – considering suicide risk when treating adolescent depressionN Engl J Med3552722317192536
   PubMed Web of Science ®Google Scholar
• Somerset Pharmaceuticals I2006EMSAM(r) Selegiline Transdermal SystemPrinceton
   Google Scholar
• SunderlandTCohenRMMolchanS1994High-dose selegiline in treatment-resistant older depressive patientsArch Gen Psychiatry51607157519005
   PubMed Web of Science ®Google Scholar
• TaavitsainenPAnttilaMNymanL2000Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomesPharmacol Toxicol862152110862503
   PubMedGoogle Scholar
• TaylorJJWilsonJWEstesLL2006Linezolid and serotonergic drug interactions: a retrospective surveyClin Infect Dis43180716779744
   PubMed Web of Science ®Google Scholar
• WalkerSEShulmanKITailorSAGardnerD1996Tyramine content of previously restricted foods in monoamine oxidase inhibitor dietsJ Clin Psychopharmacol1638388889911
   PubMed Web of Science ®Google Scholar
• YoudimMBHFinbergJPMLajthaA1983Monoamine oxidaseHandbook of neurochemistry Enzymes in the nervous systemNew YorkPlenum Press293313
   Google Scholar